U.S. markets closed
  • S&P 500

    4,223.70
    -22.89 (-0.54%)
     
  • Dow 30

    34,033.67
    -265.66 (-0.77%)
     
  • Nasdaq

    14,039.68
    -33.17 (-0.24%)
     
  • Russell 2000

    2,314.69
    -5.38 (-0.23%)
     
  • Crude Oil

    71.65
    -0.47 (-0.65%)
     
  • Gold

    1,812.50
    -43.90 (-2.36%)
     
  • Silver

    27.05
    -0.64 (-2.32%)
     
  • EUR/USD

    1.2000
    -0.0132 (-1.09%)
     
  • 10-Yr Bond

    1.5690
    +0.0700 (+4.67%)
     
  • GBP/USD

    1.3990
    -0.0093 (-0.66%)
     
  • USD/JPY

    110.6700
    +0.6360 (+0.58%)
     
  • BTC-USD

    38,489.10
    -1,505.25 (-3.76%)
     
  • CMC Crypto 200

    954.66
    -37.82 (-3.81%)
     
  • FTSE 100

    7,184.95
    +12.47 (+0.17%)
     
  • Nikkei 225

    29,291.01
    -150.29 (-0.51%)
     

Greenwich LifeSciences' Stock Is Trading Higher After Breast Cancer Immunotherapy Shows 0% Recurrences Over 5 Years Follow-up

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Greenwich LifeSciences Inc (NASDAQ: GLSI) has announced the abstract results of the final 5-year immune response data of the Phase 2b trial at the 2021 AACR Annual Meeting.

  • The company plans to publish the poster, the abstract, and an audio recording tomorrow in a joint press release.

  • Potent immune response data, supports the previously reported clinical outcome of 0% metastatic breast cancer recurrences over five years of follow-up.

  • A statistically significant peak immunity was reached after six months of GP2 treatment as measured in both a GP2 specific CD8 T cell dimer binding assay and a delayed-type-hypersensitivity (DTH) skin test.

  • HER2 3+ population immune response was similar to the HER2 1-2+ population immune response, suggesting the potential to treat the HER2 1-2+ population with GP2 immunotherapy in combination with trastuzumab (Herceptin) based products and other clinically active agents.

  • GP2 is immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.

  • Price Action: GLSI shares are trading 15.8% higher at $58.5 in premarket trading on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.